Actinium Pharmaceuticals Aktie

1,32 EUR -0,03 EUR -2,07 %

19:06:06

STU

1,58 USD -0,04 USD -2,35 %

21:07:18

BTT

Actinium Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.42,59 Mio. EUR

Div. Rendite0,00%

WKNA2QA48

ISINUS00507W2061

SymbolATNM

Actinium Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

14.06.24PR NewswireActinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

11.06.24PR NewswireActinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

10.06.24PR NewswireActinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclea...

15.05.24PR NewswireActinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity

15.05.24PR NewswireActinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients...

13.05.24PR NewswireActinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Societ...

07.05.24PR NewswireActinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

18.04.24PR NewswireActinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European ...

01.04.24PR NewswireActinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Pre...

26.03.24PR NewswireActinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

11.03.24PR NewswireActinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand

26.02.24PR NewswireActinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Tran...

23.02.24PR NewswireActinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Tr...

02.01.24PR NewswireActinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

11.12.23PR NewswireActinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

11.12.23PR NewswireActinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia

08.12.23PR NewswireActinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Expos...

06.11.23PR NewswireActinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations

02.11.23PR NewswireActinium Pharmaceuticals to Attend Bio-Europe Munich 2023

02.11.23PR NewswireActinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavor...

04.10.23PR NewswireActinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy

27.09.23PR NewswireActinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting

07.09.23PR NewswireActinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO

31.08.23PR NewswireActinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting

21.08.23PR NewswireActinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress

24.07.23PR NewswireActinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit

26.06.23PR NewswireSNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data

23.06.23PR NewswireActinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting

16.06.23PR NewswireActinium Pharma to Present at the Maxim Healthcare Virtual Conference

14.06.23PR NewswireActinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation Summit

12.06.23PR NewswireActinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress

07.06.23PR NewswireActinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes

22.05.23PR NewswireActinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and...

11.05.23PR NewswireActinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)

10.05.23PR NewswireActinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals Day

28.04.23PR NewswireActinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the...

27.04.23PR NewswireActinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transpl...

19.04.23PR NewswireActinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting

19.04.23PR NewswireActinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Ann...

03.04.23PR NewswireActinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones

Actinium Pharmaceuticals News

Actinium Pharmaceuticals News: auf dieser Seite finden Sie alle Actinium Pharmaceuticals News und Nachrichten zur Actinium Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Actinium Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Actinium Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.